Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Cancer Therapy & Research Center Stories

2011-02-14 06:30:00

CALGARY, Feb. 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from a U.S. Phase 2 clinical trial  (REO 017) using intravenous administration of REOLYSIN((R)) in combination with gemcitabine (Gemzar((R))) in patients with advanced pancreatic cancer. The trial is being conducted at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio (CTRC). The Principal...

2009-02-04 11:15:00

CALGARY, Feb. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) and the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA) announced a broad preclinical and clinical collaboration involving up to five, open-label, Phase 2 studies exploring the use of REOLYSIN(R) in combination with chemotherapy for various cancer indications. These indications are expected to include melanoma,...

2008-09-15 12:00:35

SCOTTSDALE, Ariz., Sept. 15 /PRNewswire/ -- Carefx Corporation today announced that the nationally recognized Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio, Texas, has gone live after a 90-day implementation with Fusion from Carefx(R), an interoperability platform that aligns patient data across multiple applications to provide a complete view of patient health history. One of only three National Cancer Institute-designated...

2008-09-08 12:00:41

CALGARY, Sept. 8 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San...

2008-06-20 03:00:29

CALGARY, June 20 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy and Research Center, University of Texas...

2007-08-09 12:04:00

Michael J. Wick, Ph.D., a recognized leader in the research of new anti-cancer drugs, has been named director of preclinical research at South Texas Accelerated Research Therapeutics (START). He will join the START team on Sept. 3. Dr. Wick comes to START from the Cancer Therapy & Research Center's (CTRC) Institute for Drug Development, where he was director of preclinical research. He is a recognized expert in the testing of novel therapies in animal models of human cancer....

2007-08-08 12:09:12

Chris H. M. Takimoto, M.D., Ph.D., an internationally recognized leader in the development of new anti-cancer drugs, has been named director of pharmacology at South Texas Accelerated Research Therapeutics (START). Dr. Takimoto comes to START from the Cancer Therapy & Research Center's Institute for Drug Development, where he was pharmacology director and held the Zachry Chair of Translational Research. START, a clinical research organization focused on developing new anti-cancer...

2007-07-20 12:07:37

SAN ANTONIO, July 20 /PRNewswire/ -- The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung. CTRC is one of only three sites in the United States, and the only in Texas, enrolling patients. The novel anti-cancer therapy, REOLYSIN(R), is a living virus, not...